Evaluation of clinical prognostic factors in Polish interferon beta-1b treated multiple sclerosis patients | Zendy

Anna Pietrzak | Zendy; Alicja Kalinowska-Łyszczarz | Zendy; Wojciech Kozubski | Zendy; S. Michalak | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Evaluation of clinical prognostic factors in Polish interferon beta-1b treated multiple sclerosis patients

Author(s) -

Anna Pietrzak,

Alicja Kalinowska-Łyszczarz,

Wojciech Kozubski,

S. Michalak

Publication year - 2019

Publication title -

neurologia i neurochirurgia polska

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.484

H-Index - 26

eISSN - 1897-4260

pISSN - 0028-3843

DOI - 10.5603/pjnns.a2019.0060

Subject(s) - medicine , multiple sclerosis , interferon beta 1b , predictive value , disease , interferon beta , physical therapy , immunology

Prompt successful control of disease activity in multiple sclerosis (MS) patients improves outcomes. Therefore, tools to aid drug selection and detect non-responders are urgently needed. Although several biochemical markers for predicting response to treatment have been proposed, clinical markers involving relapses, imaging activity and disability progression in the initial years of therapy remain competitive and appear cost-effective in a real-life setting. The aim of this study was to evaluate the prognostic value of select clinical scores in interferon beta-1b (IFNβ-1b) treated MS patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research